Latest Press Release on Pharmaceutical

La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders
SAN DIEGO - La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company”) today announced that its Special Meeting of Stockholders, which was convened on October 30, 2009, was adjourned to November 6, 2009 at 11:00 a.m., local time, at 4225 Executive Square, Suite

---

Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
NOVATO, Calif., Nov. 4 -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP), today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Me...

---

Affymax and Takeda Announce Hematide™ Publication in the New England Journal of Medicine
PALO ALTO, Calif., & DEERFIELD, Ill. - Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from a Phase 2 clinical trial of Hematide™ showing that Hematide increased hemoglobin and reduced or eliminated the need

---

Clarient Reports 2009 Third Quarter; Nine Month Results
ALISO VIEJO, Calif., Nov. 3 -- Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today ...

---

Reflect Scientific Consolidates Cryometrix Product Line to Montana Facility
OREM, UT -- 11/03/09 -- Reflect Scientific, Inc. (OTCBB: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical and transportation industries announced the integration of its Cryometrix operation into its Bozeman, ..

---

AllTranz Awarded $4 Million Research Grant by NIH and NIDA
LEXINGTON, Ky. - AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of t

---

West Announces Third Quarter 2009 Results
LIONVILLE, Pa., Nov. 3 -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its results for the third quarter of 2009. Summary comparative results were as follows: ($millions, except per-share data) Three Mont...

---

Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference
ROCKVILLE, Md., Nov. 3 -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the AACR-NCI-EORTC Intern...

---

Biosimilars of TNF-alpha Inhibitors Stand to Erode Over $9 Billion in Brand Sales in the U.S. and Europe by 2018
WALTHAM, Mass., Nov. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in br...

---

Biostar Pharmaceuticals, Inc. Significantly Increases Rural Supply Network to 3,500 Sales Outlets
XIANYANG, China, Nov. 3 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical ...

---

Teva Introduces Fexofenadine HCl and Pseudoephedrine HCl Extended-Release Tablets; An Alternative to Allegra-D® 12 Hour Tablets
JERUSALEM - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis U.S. allergy treatment Allegra-D® 12 Hour (fex

---

Cutting Edge Information Sees Burst of Innovation From Pharma and Biotech, Studies Regulatory Atmosphere
RESEARCH TRIANGLE PARK, NC -- 11/03/09 -- The pharmaceutical and biotechnology industries are on the verge of both a burst of innovative new products and a change in mindset from stereotypical "pill pushers" to breaking through to the vanguard of h..

---

Melanoma Research Foundation Leads Unprecedented Collaboration for Melanoma Research
Patient advocacy group, research community and pharmaceutical companies join forces for new breakthroughs in treatment; clinical trials to begin in 2010 HILLSBOROUGH, N.J., Nov. 3 /PRNewswire-USNewswire/ -- For more than a decade, there have been no new therapie...

---

Reportlinker Adds Contract Pharmaceutical Manufacturing, Research and Packaging
NEW YORK, Nov. 3 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Contract Pharmaceutical Manufac...

---

FDA Approves New Salix Product Exclusively in Catalent’s Zydis® Fast Dissolve Technology
SOMERSET, N.J. - Catalent Pharma Solutions, one of the leading advanced drug delivery technology providers to the pharmaceutical industry, announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Metozolv™ ODT (orally disintegrating tablets) metoclo

---

Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
POINT RICHMOND, Calif., Nov. 5 -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, tod...

---

Premier Research's Functional Sourcing Services Expand to Eastern Europe
PHILADELPHIA, Nov. 3 /PRNewswire/ -- Premier Research Group Limited, the international pharmaceutical and medical device services company, announces the expansion of their Functional Sourcing resources to Eastern Europe providing their clients further cost savings within an already cost-eff...

---

Pharmaceutical Speaker Programs an Important Source of Medical Education, Says Cutting Edge Information
RESEARCH TRIANGLE PARK, NC -- 11/03/09 -- Like many other marketing activities within the industry, pharmaceutical speaker programs -- and the physician-industry relationships that they consist of -- are under attack, most recently by the Boston Gl..

---

Alnara Pharmaceuticals Announces Appointment of Lee R. Brettman, M.D., FACP, to Chief Medical Officer
CAMBRIDGE, Mass. - Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced the appointment of Lee R. Brettman, M.D., FACP, to the newly created position of chief medical off

---

Simcere Pharmaceutical Group to Announce 2009 Third Quarter Earnings on Monday, November 16, 2009
NANJING, China, Nov. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in...

---

Mr. David Kennedy joins Girindus as Director of Operations; Dr. Kathryn Ackley assumes leadership of Project Management
CINCINNATI - Girindus America, Inc., a service provider to the pharmaceutical industry and a leading manufacturer of therapeutic oligonucleotides, is pleased to announce that Mr. David Kennedy has joined Girindus as Director of Operations. Mr. Kennedy will report directly to Dr. F. Mark

---

Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
NASHVILLE, Tenn., Nov. 2 -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that Chief Executive Officer A.J. Kazimi and Chief Commercial Officer...

---

iMedicor Receives Statement of Work from Franklyn Ideas
NANUET, N.Y. - iMedicor (OTCBB: VMCI) today announced it has received a Scope of Work (SOW) order from its partner, Franklyn Ideas, LLC (Franklyn) on behalf of one of its major pharmaceutical clients. The project calls for the direct marketing of pharma products via iMedicor&rsqu

---

ICON Selected by Lilly to Oversee its Clinical Data Management in Japan
DUBLIN - ICON plc, (NASDAQ:ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has signed an extension to its strategic agreement with Eli Lilly and Company (NYSE:LLY) to manage

---

Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roche's Actemra for Rheumatoid Arthritis
WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 98 percent of surveyed rheumatologists indicate they will prescribe Roche's Actemra, an interleukin-6 inhibitor, ...

---